HENLIUS BIOTECH(2696.HK):STRONG PRODUCT SALES IN 1Q
Fu Hong Han Lin (2696.HK): Achieving annual profit for the first time, two-wheel drive promotes innovation/internationalization
HENLIUS BIOTECH(2696.HK):ANTICIPATING SUSTAINED PROFITABILITY
Fu Hong Han Lin (02696.HK): Continued product release accelerates overseas market development
Fu Hong Han Lin (2696.HK) Investment Value Analysis Report: Cash flow has reached a positive inflection point, and the future can be expected for an evergreen foundation
Tianfeng Securities: Fu Hong Hanlin (02696) The innovation/internationalization process is progressing steadily, and the target price is HK$19.43
Fu Hong Han Lin (02696.HK): Starting with biosimilars, the innovation/internationalization process is progressing steadily
CMB International: Maintaining Fu Hong Hanlin's (02696) “Buy” Rating Target Price Raised to HK$18.65
Fu Hong Han Lin (02696.HK): ASCO GI Conference Announces Positive Data to Show Innovative Strength
Fu Hong, Han Lin (2696.HK): Biosimilar drugs and innovative drugs generate two rounds, revenue structure is reasonable, and prospects for continued profit
Fu Hong Han Lin (02696.HK): Commercial growth is rapid, and the BIOPHARMA platform is beginning to appear
Fu Hong Han Lin (2696.HK): Biosimilar Drug+Innovative Antibody Drug Combinations Strike
Fu Hong Han Lin (2696.HK): Capacity expansion pushes the company to achieve self-hematopoiesis as soon as possible, further consolidating the integrated R&D, production and marketing platform
Fuhong Hanlin (2696.HK) 2021 performance announcement review: Continued strengthening of comprehensive strength and the path towards BIOPHARMA
Fu Hong Han Lin (02696.HK): Product pipeline enters harvest period
Fuhong Hanlin-B (02696.HK) 2021 Interim Report Review: Sales volume is obvious, total R&D investment maintains efficiency improvement
Fu Hong Han Lin (02696.HK): PD-1 is progressing rapidly and is expected to become MSI-H's first treatment product in China
Fuhong Hanlin-B (02696.HK): Strategic adjustment Fuhong Hanlin opens a new stage of diversified innovation
Fuhong Hanlin-B (2696.HK) 2020 Results Announcement Review: The commercialization of the three major similar drugs went smoothly and the internationalization strategy progressed steadily
Fuhong Hanlin-B (02696.HK): Adalimumab approved for marketing and is gradually being harvested in research pipelines
No Data